EarlyMIND real-world efficacy data: Tafasitamab + lenalidomide in R/R DLBCL

Real-world data from the multicenter, retrospective EarlyMIND study, published by Brisou et al. in Haematologica, analyzed the efficacy of tafasitamab + lenalidomide in 186 European patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Patients received second-line (2L cohort; n = 105) to fourth-line (3L + 4L cohort; n = 81) treatment through the French Early Access Program (EAP). The primary endpoint was best objective response (BOR), defined as complete response (CR) or partial response (PR) assessed using 2007 International Working Group response criteria for malignant lymphoma. 

Key data: The median age was 78 years. At a median follow-up of 8.2 months, the BOR was 46.8%, with a CR rate of 29.0%. The BOR was 50.5% in the 2L cohort and 42.0% in the 3L + 4L cohort. The median time to BOR was 4 cycles. The median progression-free survival (PFS) was 4.7 months, and the median overall survival (OS) was 10.0 months in the total cohort. The median duration of response (DoR) was not reached in patients with CR.

Key learning: These real-world data show clinical benefit with tafasitamab + lenalidomide in R/R DLBCL, which may potentially address an unmet treatment need in patients with advanced age or frail status.